Intec Closes Merger with Decoy Biosystems BioSpace
#Acquisition #Public Trading #Management Changes
Intec Announces $30 Million Private Placement Ahead of Decoy Merger
#Investment #Acquisition #Public Trading
Intec Pharma and Decoy Biosystems Announce Merger Agreement
#Acquisition, Management Changes
Intec Pharma Announces Pricing of $4.9 Million Registered Direct Offering
#Investment
Intec Pharma Reports First Quarter 2020 Financial Results and Provides Corporate Update
#Investment #Partners
Intec Pharma Issues Letter to Shareholders
#Partners #Investment #Management Changes
Intec Pharma Announces $10 Million Ordinary Shares Purchase Agreement With Aspire Capital
#Investment
Intec Pharma tanks after Parkinson's trial failure
#Customers
Intec Pharma Announces Publication of Article Reviewing Accordion Pill's Unique Gastric Retention Platform in Therapeutic Delivery
#Partners #Expand
Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders
#Customers #Partners
Intec Pharma Announces Results From Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Were Presented at the XXIV World Congress on Parkinson's Disease and Related Disorders
#Customers
Intec Pharma Granted European Patent
#Partners
Intec Pharma Announces Research Collaboration Agreement With Merck
#Partners
Intec Pharma's Data from Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Accepted for Presentation at the XXIV World Congress on Parkinson's Disease and Related Disorders
#Customers
Intec Pharma Reports Last Patient Last Visit in Pivotal Phase 3 Trial of Accordion Pill™ Carbidopa/Levodopa for the Treatment of Advanced Parkinson's Disease Patients BioSpace
#Customers
Intec Pharma Reports Positive Results from Pharmacokinetic Study of Accordion Pill™ Carbidopa/Levodopa 50/500 mg Dosed Three Times Daily
#Customers
Intec Pharma Advances Medical Cannabinoid Development Program With Dosing of First Patient in a Phase 1 Pharmacokinetic Study of Accordion Pill-THC
#Investment, Expand
Intec Pharma raises $35.4m on Nasdaq at 18% discount
#Investment
Intec Pharma Announces Public Offering of Ordinary Shares on Nasdaq
#Investment #Public Trading
Intec Pharma raising $57.5m on Nasdaq
#Investment
Intec Pharma Reports Clinical Results From Phase I Trial of Accordion Pill for Cannabinoid Therapies
#Customers
Intec Pharma Promotes Nadav Navon, Ph.D. to Chief Operating Officer
#Management Changes
Intec Pharma raises $10m in private placement
#Investment
Intec Pharma To Raise $46M In IPO
#Public Trading
Israel's Intec discussing $150M drug delivery partnership with Big Pharma company
undefined
FDA gives Phase III nod for Intec Parkinson's treatment
#Investment